Literature DB >> 20017221

Alteration in TWIST expression: possible role in paclitaxel-induced apoptosis in human laryngeal carcinoma Hep-2 cell line.

Liang Yu1, Hui-Zheng Li, Su-Mei Lu, Wen-Wen Liu, Jian-Feng Li, Hai-Bo Wang, Wei Xu.   

Abstract

AIM: To explore the relationship between alteration in the expression of TWIST, highly conserved transcription factor from the basic helix-loop-helix family, and apoptosis of Hep-2 cells induced by chemotherapeutic agent paclitaxel.
METHODS: Morphological changes of Hep-2 cells were observed by acridine orange cytochemistry staining. Viability of Hep-2 cells treated with various concentrations of paclitaxel was examined by cell proliferation assay. Apoptosis was examined by flow cytometry. The mRNA and protein expression of TWIST in response to paclitaxel at 24 hours, 48 hours, and 72 hours was examined by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting, respectively.
RESULTS: Typical morphological changes of apoptotic cells at 24 hours, 48 hours, or 72 hours after treatment wiyth paclitaxel (10x10(-9) mol/L) were observed. The cell survival rates significantly decreased in a concentration- and time-dependent manner (P=0.001). Paclitaxel-induced apoptosis increased with culture time (22.6+/-5.3% after 24 hours, 38.7+/-7.9% after 48 hours, and 52.4+/-14.3% after 72 hours; P=0.002). Both mRNA and protein expression of TWIST was markedly decreased at both mRNA levels and protein levels, at 24 hours, 48 hours, and 72 hours in the paclitaxel-induced apoptosis of Hep-2 cells (P<0.001).
CONCLUSION: TWIST, which has a significantly decreased expression in response to paclitaxel in Hep-2 cells, may play a pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20017221      PMCID: PMC2805845          DOI: 10.3325/cmj.2009.50.536

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  19 in total

1.  Promotion of microtubule assembly in vitro by taxol.

Authors:  P B Schiff; J Fant; S B Horwitz
Journal:  Nature       Date:  1979-02-22       Impact factor: 49.962

2.  An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies.

Authors:  R B Tishler; P M Busse; C M Norris; R Rossi; M Poulin; L Thornhill; R Costello; E S Peters; A D Colevas; M R Posner
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

3.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

Review 4.  Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.

Authors:  T H Wang; H S Wang; Y K Soong
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

Review 5.  Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.

Authors:  Robert Haddad; Roy B Tishler; Charles M Norris; Anand Mahadevan; Paul Busse; Lori Wirth; Laura A Goguen; Christopher A Sullivan; Rosemary Costello; Mary Ann Case; Marshall R Posner
Journal:  Oncologist       Date:  2003

6.  Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells.

Authors:  Xianghong Wang; Ming Tat Ling; Xin-Yuan Guan; Sai Wah Tsao; Hiu Wing Cheung; Davy Tak Lee; Yong Chuan Wong
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

7.  Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.

Authors:  Daniel J Haraf; Fred R Rosen; Kerstin Stenson; Athanassios Argiris; Bharat B Mittal; Mary Ellyn Witt; Bruce E Brockstein; Marcy A List; Louis Portugal; Harold Pelzer; Ralph R Weichselbaum; Everett E Vokes
Journal:  Clin Cancer Res       Date:  2003-12-01       Impact factor: 12.531

Review 8.  Head and neck cancer in the elderly: an overview on the treatment modalities.

Authors:  Kostas N Syrigos; Dimitris Karachalios; Eleni M Karapanagiotou; Christopher M Nutting; Leonidas Manolopoulos; Kevin J Harrington
Journal:  Cancer Treat Rev       Date:  2008-12-18       Impact factor: 12.111

9.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.

Authors:  F Denizot; R Lang
Journal:  J Immunol Methods       Date:  1986-05-22       Impact factor: 2.303

10.  Pharmacodynamics of taxol in human head and neck tumors.

Authors:  Y Gan; M G Wientjes; D E Schuller; J L Au
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

View more
  7 in total

1.  Down-regulation of TWIST decreases migration and invasion of laryngeal carcinoma Hep-2 cells by regulating the E-cadherin, N-cadherin expression.

Authors:  Liang Yu; Hui-zheng Li; Su-mei Lu; Jia-jun Tian; Ju-ke Ma; Hai-bo Wang; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-07       Impact factor: 4.553

Review 2.  Twist: a molecular target in cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Han-chun Chen; Dianzheng Zhang; Junjiang Fu
Journal:  Tumour Biol       Date:  2013-07-20

3.  Expression and significance of TWIST, a zinc finger transcription factor, in laryngeal carcinoma among Chinese population: a meta-analysis.

Authors:  Zhaolan Xiang; Qi Li; Aoshuang Chang; Xianlu Zhuo; Xueyuan Zhang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 4.  Targeting Twist expression with small molecules.

Authors:  Haixiang Pei; Yunqi Li; Mingyao Liu; Yihua Chen
Journal:  Medchemcomm       Date:  2016-12-02       Impact factor: 3.597

5.  cDNA cloning, overexpression, purification and pharmacologic evaluation for anticancer activity of ribosomal protein L23A gene (RPL23A) from the Giant Panda.

Authors:  Bing Sun; Yi-Ling Hou; Wan-Ru Hou; Si-Nan Zhang; Xiang Ding; Xiu-Lan Su
Journal:  Int J Mol Sci       Date:  2012-02-16       Impact factor: 6.208

6.  Magnesium Isoglycyrrhizinate Induces an Inhibitory Effect on Progression and Epithelial-Mesenchymal Transition of Laryngeal Cancer via the NF-κB/Twist Signaling.

Authors:  Jiarui Zhang; Rui Zhao; Dongliang Xing; Jing Cao; Yan Guo; Liang Li; Yanan Sun; Linli Tian; Ming Liu
Journal:  Drug Des Devel Ther       Date:  2020-12-22       Impact factor: 4.162

7.  Role and mechanism of Twist1 in modulating the chemosensitivity of FaDu cells.

Authors:  Sumei Lu; Liang Yu; Yakui Mu; Juke Ma; Jiajun Tian; Wei Xu; Haibo Wang
Journal:  Mol Med Rep       Date:  2014-05-06       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.